Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients

समान संसाधन

• Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
  द्वारा: Frerichs, Kristine A., और अन्य
  प्रकाशित: (2019)
• CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
  द्वारा: Frerichs, Kristine A., और अन्य
  प्रकाशित: (2019)
• Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab
  द्वारा: Krejcik, Jakub, और अन्य
  प्रकाशित: (2017)
• T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
  द्वारा: Verkleij, Christie P.M., और अन्य
  प्रकाशित: (2020)
• Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
  द्वारा: Frerichs, Kristine A., और अन्य
  प्रकाशित: (2021)